Trial Profile
A Phase 1, First-in-man, Multicenter, Open-label, Dose-escalation Study of Single-agent GBR 1302 in Subjects With HER2 Positive Cancers
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs ISB 1302 (Primary)
- Indications Adenocarcinoma; Breast cancer; Gastric cancer; Solid tumours
- Focus Adverse reactions; First in man
- Sponsors Glenmark Pharmaceuticals S.A.
- 15 Dec 2019 Status changed to discontinued.
- 10 Dec 2019 Status changed from discontinued to completed.
- 09 Dec 2019 Status changed from active, no longer recruiting to discontinued.